Short answer
RIGEL PHARMACEUTICALS INC (RIGL) filed an 8-K current report with the SEC on June 17, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets). Rigel completed acquisition of exclusive global rights to develop, manufacture, and commercialize VEPPANU™ (vepdegestrant).
RIGEL PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Rigel completed acquisition of exclusive global rights to develop, manufacture, and commercialize VEPPANU™ (vepdegestrant)
- $70.0 million upfront payment made to Arvinas, Arvinas affiliates, and Pfizer
- Transaction cleared Hart-Scott-Rodino review, removing a key regulatory closing condition
- Rights acquisition expands Rigel’s global oncology development and commercialization portfolio
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RIGEL PHARMACEUTICALS INC 8-K filings
Get the next RIGL 8-K as it lands
Follow RIGL for push alerts, or ask the research agent what this filing means.